Latest filing published 20 Oct 2020 for Tarsus Pharmaceuticals, Inc., €42k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +12.4%Entry US$24.50 · Close at T+365 US$27.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jason E. Tester: trading record in brief
Jason E. Tester discloses dealings in Tarsus Pharmaceuticals, Inc. to SEC (Form 4). We count 7 filings, every one of them for a trade on 20 October 2020.
No open-market sale appears; the market trades are 2 purchases worth €2.3M. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The latest filing, published on 20 October 2020, reports an open-market purchase of €42k in Tarsus Pharmaceuticals, Inc. Most trades are made public on the day they happen. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Jason E. Tester
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,125 shares@ US$16.001.8% of flowCommon StockSEC:0001209191-20-055421:2Canonical exit: 18 Jan 2021 (T+90)
- 21,575 sharesCommon StockSEC:0001209191-20-055421:0
- 3,698 sharesCommon StockSEC:0001209191-20-055421:1
- 1,434,790 sharesCommon StockSEC:0001209191-20-055421:3
- 245,966 sharesCommon StockSEC:0001209191-20-055421:4
- 71,427 sharesCommon StockSEC:0001209191-20-055421:5
- ▲
Same trade as the filing by Horowitz Limited Partnership VIII, counted once
3M USD37SEC168,750 shares@ US$16.0098.2% of flowCommon StockSEC:0001209191-20-055421:6Canonical exit: 18 Jan 2021 (T+90)
7 of 6 declarations
